Biocompatible and bioactivable terpolymer-lipid-MnO2 Nanoparticle-based MRI contrast agent for improving tumor detection and delineation
Authors:
Open Access
- 21 January 2024
- journal article
- research article
- Published by Elsevier in Materials Today Bio
- Vol. 25, 100954
Abstract
No abstract availableKeywords
Funding Information
- Canadian Institutes of Health Research (PJT-162301)
- Natural Sciences and Engineering Research Council of Canada (EQPEQ 440689-13)
- Canada Council for the Arts (702-18-0051)
- University of Toronto - St George Campus
- Mitacs
This publication has 74 references indexed in Scilit:
- Uptake Mechanism of ApoE-Modified Nanoparticles on Brain Capillary Endothelial Cells as a Blood-Brain Barrier ModelPLOS ONE, 2012
- Manganese-based MRI contrast agents: past, present, and futureTetrahedron, 2011
- Revisiting an old friend: manganese‐based MRI contrast agentsWIREs Nanomedicine and Nanobiotechnology, 2010
- Gadolinium-Based Magnetic Resonance Contrast Agents at 7 TeslaInvestigative Radiology, 2010
- The use of magnetic resonance imaging for image‐guided brachytherapyJournal of Medical Imaging and Radiation Oncology, 2010
- Biodistribution of gadolinium‐based contrast agents, including gadolinium depositionJournal of Magnetic Resonance Imaging, 2009
- Method for Analysis of Nanoparticle Hemolytic Properties in VitroNano Letters, 2008
- Gadolinium and nephrogenic systemic fibrosisKidney International, 2007
- Nutritional aspects of manganese homeostasisMolecular Aspects of Medicine, 2005
- Safety and optimum concentration of a manganese chloride–based oral MR contrast agentJournal of Magnetic Resonance Imaging, 1994